Toggle Main Menu Toggle Search

Open Access padlockePrints

Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Lookup NU author(s): Professor Fai Ng


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Objectives To define disease activity levels, minimal clinically important improvement (MCII) and patient acceptable symptom state (PASS) with the primary Sjogren's syndrome (SS) disease activity indexes: European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) and EULAR SS patient reported index (ESSPRI).Methods For 790 patients from two large prospective cohorts, ESSDAI, physician evaluation of disease activity, ESSPRI and patients' satisfaction with their current health status were recorded. Receiver operating characteristic curve analyses and anchoring methods were used to estimate disease activity levels of ESSDAI and the PASS of ESSPRI. At follow-up visit, patients and physicians assessed, respectively, whether symptoms and disease activity have improved or not. An anchoring method based on this evaluation was used to estimate MCII of ESSDAI and ESSPRI.Results Low-activity (ESSDAI<5), moderate-activity (5 <= ESSDAI <= 13) and high-activity (ESSDAI >= 14) levels were defined. MCII of ESSDAI was defined as an improvement of at least three points. The PASS estimate was defined as an ESSPRI<5 points and MCII as a decrease of at least one point or 15%.Conclusions This study determined disease activity levels, PASS and MCII of ESSDAI and ESSPRI. These results will help designing future clinical trials in SS. For evaluating systemic complications, the proposal is to include patients with moderate activity (ESSDAI >= 5) and define response to treatment as an improvement of ESSDAI at least three points. For addressing patient reported outcomes, inclusion of patients with unsatisfactory symptom state (ESSPRI >= 5) and defining response as an improvement of ESSPRI at least one point or 15% seems reasonable.

Publication metadata

Author(s): Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dorner T, Tzioufas A, Gottenberg JE, Laque RS, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zeron P, Vitali C, Mariette X, EULAR Sjogren's Task Force

Publication type: Article

Publication status: Published

Journal: Annals of the Rheumatic Diseases

Year: 2016

Volume: 75

Issue: 2

Pages: 382-389

Print publication date: 01/02/2016

Online publication date: 05/12/2014

Acceptance date: 14/11/2014

ISSN (print): 0003-4967

ISSN (electronic): 1468-2060

Publisher: BMJ Publishing Group


DOI: 10.1136/annrheumdis-2014-206008


Altmetrics provided by Altmetric


Find at Newcastle University icon    Link to this publication